Company Overview
BioAlps - Western Switzerland Life Science Cluster

A unique dynamic and vibrant ecosystem where Biotech- Medtech-Nanotech-Information Technology- Digital Health - AI technologies converge

BioAlps is the life science cluster of Western Switzerland. The association is an active and growing network of research institutions, academic institutions, start-up companies and large, blue chip multinationals.

The life science sectors in BioAlps are experiencing double digit annual growth. It is the most diversified life science cluster in the world.

The BioAlps Association is supported by the Cantons of Bern, Fribourg, Vaud, Neuchâtel, Geneva, Valais, Jura and the Swiss State Secretariat for Economic Affairs.

With a mission of promoting the excellence and performance in the life science developments in this cluster at all levels: regionally, nationally and in the international arena, BioAlps is the entry point to a wealth of contacts, knowhow, knowledge and provides both personal and institutional support.

Everything that BioAlps does is geared towards innovation and nurturing creativity in research, education and business in order to enable novel products and services to reach the market efficiently and quickly.

BioAlps organises events and co organises conventions, participates in a number of international events and supports conferences promoting the cluster and offering its members a wealth of networking opportunities.

The BioAlps region includes:

• 1120 medical technology, biotechnology, pharmaceutical, healthcare and digital health companies

• 500 research laboratories

• 35'500 people employed in companies

• 5,000 researchers

• 33 research institutions, universities and university hospitals

• 18 life science parks and incubators for start-up companies

The BioAlps region offers many assets for attracting companies and start-ups:

• Strong, dynamic and economy-friendly academic research: efficient technology transfer practices

• Most favourable tax rulings and conditions in Europe, particularly for new companies and international corporate structures